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Abstract
Background: Dozens of scales and questionnaires have been used in the detection of frailty; however, a
generalized method for its screening and diagnosis is still lacking in clinical settings. FRAILTOOLS´ main objective is
to evaluate the usefulness of frailty scales in the detection of frailty in different clinical and social settings, and its
integration in management algorithms for the frail older patient.
Methods: FRAILTOOLS is an observational, longitudinal and prospective study with a follow-up of 6, 12 and 18
months. People older than 75 years old will be recruited from three separate clinical settings (acute geriatric wards,
geriatric outpatient clinics and primary care) and one social setting (nursing homes). Exclusion criteria include Mini-
mental State Examination < 20 points, and a Barthel index < 90 points, except in nursing home residents (< 40
points). The participants will be recruited in Spain, Italy, France, United Kingdom and Poland. The total sample size
will be of 1.940 subjects, 97 subjects in each clinical setting by center. A personal interview with each participant
will take place to register data on comorbidity (Charlson Index), functional (SPPB, Barthel and Lawton indexes),
cognitive (MMSE) and frailty status (Fried Phenotype, Frailty Trait Scale – short version, SHARE-FI, 35-Items
Rockwood Frailty Index, Clinical Frailty Scale, FRAIL scale and Gérontopôle Frailty Screening Tool) in the baseline
visit, month 12 and month 18 visit of follow up. At 6 month a phone call will be made to assess whether there
have been falls and to check the vital status.
Discussion: Currently, the usefulness of certain assessment tools in social and clinical settings have not been
properly assessed, including their ability to predict the individual risk for different adverse outcomes, which is the
main interest in daily practice.
The FRAILTOOLS project concentrates on providing screening and diagnostic tools for frailty in those settings
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where its prevalence is the highest and where efforts in prevention could make a significant change in the trend
towards disability.
Trial registration: Comprehensive validation of frailty assessment tools in older adults in different clinical and social
settings (FRAILTOOLS), NCT02637518 (date of registration: 12/18/2015).
Keywords: Frailty, Assessment tools, Older adults, FRAILTOOLS project
Background
From the second half of the twentieth century, life ex-
pectancy has increased in developed countries, reaching
a mean age of 83 years in countries such as Spain,
France and Italy [1, 2]. As a result, Europe is the contin-
ent with the highest proportion of older people, but also
with a higher dependency ratio rate [2].
From a health and social point of view, the older
population has increased requirements, needing special-
ized care to approach the complexity of their comorbidi-
ties [3]. On the other hand, as life expectancy increases,
the proportion of older people with any kind of disability
rises [4], which in turn increases the need for long term
care facilities. All of this leads to additional health and
social expenditure [2].
In order to address this situation, new policies are
needed, which are particularly aimed at: a) implementing
reforms in the pension system, health and care and
long-term care facilities, and b) reducing disability and
dependency. As to the latter, it is imperative to detect
the population at higher risk of disability, with the ob-
jective of implementing preventive actions [1, 2].
Within the last 20 years, health and social care profes-
sionals dedicated to the field of geriatric medicine have
made major efforts in identifying older people requiring
specialized attention that may contribute to delay or avoid
the appearance of disability. Prior to disability there is an
intermediate state known as frailty, a syndrome character-
ized by diminished capacity to respond to stressors, due to
a reduced functional reserve [3]. Frailty is a condition that
is closely associated with mortality among community
dwelling older adults, followed by organ failure, cancer
and terminal dementia [5]. This condition is also related
to other adverse outcomes such as: falls, morbidity, dis-
ability, polypharmacy, hospitalization, institutionalization
and mortality [6].
Multiple studies have been undertaken worldwide to
establish the prevalence of frailty [3, 7–9]. The data vary
according to countries reaching a percentage of up to
27.3%. A survey of 7510 community-dwelling older
adults in 10 European countries found that the preva-
lence of frailty was higher in southern than in northern
Europe [7, 10]. For instance, in Spain the prevalence of
frailty was 8.4% among institutionalized and community
dwelling persons from rural and urban settings [8]. In
Italy, in community-dwelling older adults the frailty
prevalence was 13.9% [11]. In the French population
older than 55 years-old and free of disability, around
25% are either frail or multimorbid [12]. In the nurs-
ing home setting this prevalence doubles in compari-
son with community dwelling people, reaching 68.8%
according to a number of American studies [9, 13].
As frailty is highly associated with age, we should ex-
pect an increase in the number of new cases (inci-
dence) of frailty as the European population gets
older. Published data ranges from 4% new cases in
adults aged over 65 years in Germany to 8% in adults
aged over 60 years in Spain after three years of
follow-up [14].
Dozens of scales and questionnaires have been used in
the detection of frailty [15].; however a universal oper-
ational definition of frailty or a generalized method for
its screening and diagnosis is still lacking [16]. In differ-
ent clinical scenarios where the care of the elderly is a
priority, such as primary health care or nursing homes,
it is imperative to have specific instruments in the detec-
tion of frailty according to the characteristics of each
level of care.
The FRAILTOOLS Project addresses the needs to valid-
ate scales for its application in different clinical and social
settings, and its integration in management algorithms for
the frail older patient.
Methods/design
Objectives
Main objective
 Evaluate the usefulness of frailty scales in the
detection of frailty in different clinical and social
settings.
Secondary objectives
 Establish the scale with the highest predictive value
according to the most common adverse outcomes in
frail patients.
 Design frailty detection algorithms according to the
clinical setting.
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Outcomes
Primary outcomes
Determine the predictive value of frailty scales according
to the adverse outcomes associated with frailty in people
older than 75 years old in different settings of clinical
care.
 Mortality: Data will be obtained from the official
registration of the country of the corresponding
partner from a participant who does not answer the
telephone or who does not have medical follow-up
after the last visit.
 Disability: It will be defined as a loss of one point
in the Short Physical Performance Battery (SPPB),
the loss of independence in any Instrumental
Activity of Daily Living (IADL) according to the
Lawton index, or by a reduction in ≥5 points in the
Barthel index [17–19].
 Falls: It is an event in which the participant comes
to rest inadvertently on the ground or other lower
level. Data will be collected by the participant’s
verbal recall (self-assessed) and will be registered in
the Query-Case Report Form (eCRF).
 Incident cognitive impairment: It will be defined
by a reduction of ≥2 points in the MMSE [20].
Secondary outcomes
 Performance of the instruments by clinical setting:
seven frailty assessment tools will be used in four
different levels of care. The performance of each
scale in the classification of frailty will be
established.
 Feasibility composed by two main conditions: the
percentage of people that are assessed by each tool
in each setting (adequacy) and the time for carrying
out the tool assessment. The utility of both
screening and diagnostic tools stems, among other
characteristics, from the time needed to pass them.
This characteristic is relevant mainly in settings
where the demand for attention is high and the time
to provide is limited.
 Sensitivity to change, one of the problems of many
of the tools used to assess frailty is that they have a
low sensitivity to change. This is a relevant issue in
clinical settings, where monitoring the progress of
the patient is of high value. For this purpose, we will
evaluate the change in the assessment level of
patients observed at 12 and 18 months with each of
the tools and their correlations with the changes
observed in the functional status of the patients as
assessed by SPPB.
 Qualification as screening and/or diagnosis tool:
evaluate the utility of each scale as a frailty detection
method, using pre-established criteria, based on the
prevalence of this condition in each setting and the
classification performance (Sensitivity, Specificity,
Positive and Negative Predictive Values and Likeli-
hood ratios), plus its feasibility, and its sensitivity to
change.
Type of study
This is an observational, longitudinal and prospective
study.
Population
People aged ≥75 years, will be recruited from different
clinical and social settings, including acute geriatric
wards, geriatric outpatient clinics, primary care centers
and nursing homes.
Inclusion criteria
Participants over 75 years of age, will be consecutively
selected, who have signed the informed consent and ac-
cepted their voluntary participation.
Exclusion criteria
 General exclusion criteria are:
○ MMSE score ≤ 20 points.
○ Terminal illness (life expectancy ≤6 months).
 A Barthel Index < 90 in patients from the Acute
Geriatric Unit, Outpatient Geriatric Consultation
and primary care centers.
 A Barthel Index < 40 in residents from nursing
homes.
Recruitment process and sample size
Prior to the start of the recruitment process, Ethics
Committee approval and any other regulatory approvals
will be obtained.
Potential candidates will be assessed by geriatricians or
other suitably qualified members of the study team and
will provide information to each participant about the
study and their participation. After each participant has
read the participant information sheet and given written
informed consent to participate, their eligibility criteria
will be assessed and if satisfied, will be enrolled into the
study. The participant’s right to decline their participa-
tion in the study at any stage without any explanation
will be respected. The participant can withdraw the
study at any time without giving reasons and with no
detriment in their usual medical care. If a participant
withdraws from the study after a prior inclusion, this in-
formation will be passed immediately to the principal in-
vestigator and the procedure for their exclusion will take
place.
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Each one of the participating centers has a scientific
interest in the field of frailty (Table 1). The participants
will be recruited in Spain, Italy, France, United Kingdom
and Poland.
Contact with hospitals, primary care and nursing
homes will be made through the coordinators of the cor-
responding Health Centers, requesting the authorization
for the recruitment process and signing the proper doc-
uments to formalize their participation.
In order to determine the sample size, we have used
two assumptions:
1. The sample size is calculated according to the
methodology of Peduzzi et al. [21] for a model of 4
variables. The variables included are: age, gender
and Charlson index as covariates and frailty status
as the main independent variable of interest.
2. The outcomes to be assessed will be death, falls,
disability and deterioration in cognitive function.
Among these variables, death is the least frequent
and generates the highest sample size therefore it
can be used for the other three outcomes.
Although there are some little differences in the
mortality rates among the five European countries
that participate in this project; the mean mortality
rate for people aged ≥75 years in these countries is
10% annually. Therefore, in 18 months it will be
15%, which is the follow-up period forecasted in
FRAILTOOLS project.
Within these assumptions the lower limit of the 1-α
confidence interval for the accepted number of success
is 355 and 388 participants in each setting of care for 95
and 99% CI, respectively. This number must be in-
creased with the forecasted lost to follow-up, in 20%. As
a whole, the final sample size is established in 485 per-
sons per setting, which means a final figure of 1940 per-
sons. Thus, every partner will be responsible for the
enrolment, assessment and follow-up of 388 older adults
(97 per setting).
Follow-up
The follow-up will be of 18 months as maximum. In
order to avoid memory bias, a phone call will be made
in month 6 after the inclusion to assess whether there
has been a fall or death. At 12 and 18months, a personal
interview with each participant will take place to register
data on functional status (SPPB, Barthel and Lawton in-
dexes), cognitive status (MMSE) and frailty status (Fried
Frailty Phenotype Criteria, o Frailty Trait Scale – short
version, SHARE-FI scale, 35-Items Rockwood Frailty
Index, Clinical Frailty Scale, FRAIL scale and Géronto-
pôle Frailty Screening Tool) (Table 2).
In case a participant passed away during the follow-up
phase of the study, the information will be recorded in
the eCRF of the follow-up visits at 6, 12 or 18 months. A
document to record death will be filled as an adverse
event unrelated to the study. Data regarding mortality
will be obtained from the official register of the country
of the corresponding partner.
The principal investigator will ensure that the study
takes place according to the protocol, to Good Clinical
Practice principles, and to the Declaration of Helsinki of
1996. At the baseline visit, frailty assessment tools will
be completed. Variables such as socio-demographic data,
comorbidities, functional and cognitive status will also
be assessed.
The Investigator will ensure that this study is con-
ducted in accordance with the protocol, the principles of
the Declaration of Helsinki, International Conference of
Harmonization Guidelines for Good Clinical Practice
and in full conformity with relevant regulations.
All substantial amendments to the original approved
documents will also be sent to the appropriate Ethics
Committee and Regulatory Authority (if applicable) for
their revision.
The study staff will ensure that the subject’s anonymity
is maintained. The subjects will be identified only by a
subject code in the eCRF and any electronic database.
All documents will be stored securely and only access-
ible by study staff and authorized personnel. The study
will comply with the Data Protection Legislation in each
country.
Subjects will not receive any economic compensation
for participation in this study.
Questionnaires and tools assessed
In the Query-Case Report Form the following informa-
tion will be collected:
 Socio-demographic data: age, gender, race, marital
status, education, cohabitation, need for caregiver,
setting in which the subject is recruited, country of
origin.
 Comorbidities:
Table 1 Participating centers
Country Participating center
Spain Fundación para la Investigación Biomédica del
Hospital Universitario de Getafe (FIB-HUG)
Italy Centro Medicina dell’Invecchiamento (CEMI)/
Università Cattolica del Sacro Cuore
France Gérontopôle de Toulouse
United Kingdom Aston Universitya
Poland Department of Internal Medicine and Gerontology
(DIMG) and Division of Internal Medicine of the
University Hospital of the JUMC
aAston University replaced Diabetes Frail Limited (DIFRAIL) in United
Kindgdom as participating center
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○ Charlson Comorbidity Index [22]: This scale
predicts the ten-year mortality for a patient by
classifying or weighting comorbid conditions. It
consists of 19 issues each of which was weighted
according to their potential influence on
mortality.
 Functional status:
○ Barthel Index [18]: Functional assessment scale
that measures the subject’s capacity to perform
ten activities of daily living in an independent
manner.
○ Lawton Index [17]: Instrument to assess the
individual’s capacity to perform IADL
independently. These skills are considered more
complex than the basic activities of daily living
as measured by the Barthel Index.
○ Short Physical Performance Battery [23]: Test
designed to measure functional status and
physical performance by combining the results of
the gait speed, chair stand and balance tests.
 Cognitive status:
○ Mini Mental State Examination – MMSE [20]: It
is a widely used test to screen patients for
cognitive impairment and to track changes in
cognitive functioning over time. It evaluates
seven cognitive domains including orientation to
time and place, repetition, verbal recall, attention
and calculation, language and visual construction.
 Frailty assessment scales:
○ Fried’s Frailty Phenotype Criteria [3]: Well-
known scale to diagnose frailty. It is based on the
biological causative theory and shows predictive
validity for poor health outcomes across a wide
range of illnesses and procedures. This tool com-
bines a total of five variables, three of them self-
referred: weight loss, exhaustion and reduced
physical activity; and other two objective vari-
ables: weakness assessed by grip strength, and
slowness measured by gait speed.
○ Frailty Trait Scale – short version [24]: Scale that
emerged from a population study in Toledo,
Spain. It evaluates three dimensions: nutrition
(BMI), physical activity (PASE), and nervous
system (balance test).
○ SHARE Frailty Instrument (6,7): Screening
instrument for frailty proposed for the primary
Table 2 Flow of the study
Time point Baseline
T1
Follow up
Month 6
T2
Month 12
T3
Month 18
T4
ENROLLMENT:
Eligibility screen X
Informed consent X
ASSESMENTS:
Socio-demographic data X X X
Charlson Comorbidity Index X X X
Barthel Index X X X
Lawton Index X X X
SPPB X X X
MMSE X X X
Fried’s Frailty Phenotype Criteria X X X
Frailty Trait Scale – short version X X X
SHARE Frailty Instrument X X X
35-Items Rockwood Frailty index X X X
FRAIL scale X X X
Gérontopôle Frailty Screening Tool X X X
Clinical Frailty Scale X X X
OUTCOMES:
Disability X X X
Mortality X X X
Falls X X X
Incident cognitive impairment X X X
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health care setting. It explores five dimensions:
exhaustion, loss of appetite, weakness measured
by grip strength, difficulty walking and low
physical activity.
○ 35-Items Rockwood Frailty index [25]: Scale
with 35 items, based on data routinely collected
as part of a geriatric assessment. It includes items
on chronic diseases, basic and instrumental
disabilities in activities of daily living, serum
vitamin D, cognition, physical performance,
nutrition, visual and hearing impairment.
○ FRAIL scale [26]: Self-assessed short
questionnaire, taking into account five different
aspects: Fatigue, Resistance, Ambulation, Illness
and Loss of weight. It does not require
measurements or administration by healthcare
professionals.
○ Gérontopôle Frailty Screening Tool [27]: It is a
short questionnaire addressed to primary care
physicians with a total of six questions assessing
the individual’s social, physical, functional and
cognitive situation. There is no clear cut-off point
to classify the patient as frail or not.
○ Clinical Frailty Scale o Rockwood modified [28]:
Scale that uses clinical descriptors and
pictographs to stratify older adults according to
level of vulnerability. It mixes items such as
comorbidity, cognitive impairment and disability.
According to the authors, it provides predictive
information about mortality or institutionalization
similar to that of other established tools.
The study is ongoing. Follow-up visits finished on No-
vember 30th. Statistical analysis will be run until April
1st, 2019. The publication of the full results will take
place on the second half of 2019.
Statistical analysis
FRAILTOOLS aims to 1) assess the selected instruments
(scales) for both screening and diagnosis purposes in
each of the four settings: acute geriatric wards, geriatric
outpatient clinics, primary care centers and nursing
homes; and 2) explore the sequential or consecutive as-
sessment of the older population amongst settings.
Regarding the first objective of the analysis, we will as-
sess the associations of each of the seven scales with the
outcome for each setting and outcome through logistic
regressions using age, sex and Charlson index as possible
confounders. With these variables, we will construct
three logistic regression models: unadjusted, adjusted by
age and gender, and adjusted by age, gender and Charl-
son Index. Firstly, we will compute the classification per-
formance (sensitivity, specificity, ROC curve, AUC,
predictive values, likelihood ratios) for each model. This
way, we will assess the most accurate scale for both
screening (the most sensitive tool) and diagnostic pur-
poses (the most specific tool), for each setting and for
each outcome. Secondly, we will study the feasibility of
the models, considering the time needed for the scale
and the percentage of patients that can be evaluated per
case.
Combining both outcomes by creating an index (clas-
sification performance * proportion of evaluated pa-
tients), we will determine the best scale (maximum value
of the index) per setting for both screening and diagno-
sis. Thirdly, we will evaluate the sensitivity to change of
the scales and the covariance of the scales with other
measures as the SPPB through a mixed linear model.
For the second objective, we will first analyze the ex-
ternal validity of each model by using the data of each
setting in the other models during the last phase of the
project. Afterwards, we will evaluate which set of instru-
ments is more appropriate for sequential or consecutive
assessment when patients move between different set-
tings: e.g. from nursing homes to geriatrics wards.
Discussion
Frailty is the main risk factor for the appearance of dis-
ability [29]; once disability arises, recovery is unlikely
[30]. Frailty can be reversed spontaneously [29, 31] or by
exercise-based interventions [32].
In view of its prognostic power to cause disability, its
high prevalence and potential reversibility, frailty is the
ideal objective to approach the disability challenge in
our elders [29, 31].
Many studies have demonstrated the utility of certain
assessment tools to evaluate frailty in populations, how-
ever, the individual risk for disability has not been prop-
erly evaluated, which is the main interest in the daily
clinical and social settings [14, 33]. Indeed, so far, no
published studies have validated the usefulness and feasi-
bility of frailty tools in geriatric units, primary care cen-
ters and nursing homes; where the prevalence of people
with frailty is high and the risk to develop disability is
palpable. FRAILTOOLS study will contribute to validate
tools to screen and diagnose frailty in different clinical
scenarios; with the purpose of implementing it in daily
practice and creating diagnostic algorithms according to
the setting assessed.
Therefore, it can be said that the FRAILTOOLS pro-
ject is an original initiative; relevant, by focusing its ef-
forts on the main risk factor for disability; pertinent,
concentrating on providing screening and diagnostic
tools for frailty in settings where its prevalence is the
highest and where efforts in prevention could make a
significant change in the trend towards disability.
FRAILTOOLS also contributes to the initiative of the
European’s Commission on Frailty, Integrated care and
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multi-chronic conditions by: 1) the application of coor-
dinated and innovative preventive measures, 2) develop-
ment and implantation of screening and early diagnostic
programs of frailty, which include the optimization of
functional capacity and the development of guidelines to
manage frailty, 3) improve healthcare systems, 4) imple-
ment health promotion strategies, and 5) facilitate the
exchange of Good Clinical Practice and expanding
knowledge networks, and 6) promote innovation in
healthcare at European level.
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